Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
CardioVascular and Interventional Radiology
Erschienen in:

14.05.2024 | Clinical Investigation

Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere

verfasst von: Gyoung Min Kim, Do Young Kim, Jong Yun Won, Sungmo Moon, Seung Up Kim, Beom Kyung Kim

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the treatment outcomes of glass and resin microspheres for the treatment of hepatocellular carcinoma (HCC) and evaluate the prognostic factors that influence the outcomes.

Materials and Methods

We retrospectively reviewed 251 consecutive patients who underwent radioembolization for the treatment of HCC at a single tertiary center. Imaging responses after radioembolization were evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) 1.1. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard models were used to identify the prognostic factors.

Results

A total of 195 patients were included in this study (glass microsphere, n = 75; resin microsphere, n = 120). The complete and objective response rates were 16.0% and 50.7% in the glass microsphere group and 17.5% and 58.3% in the resin microsphere group, respectively. Median PFS was 241 days in the glass microsphere group and 268 days in the resin microsphere group (p = 0.871). Median OS was 29 months in the glass microsphere group and 40 months in the resin microsphere group (p = 0.669). The only significant prognostic factor was bilobar tumor distribution, which favored resin microspheres (p = 0.023). Procedure-related adverse events occurred more frequently in the resin microsphere group (glass, 2.7% vs. resin, 5.0%; p < 0.001).

Conclusion

Glass and resin microspheres for the treatment of HCC did not show a significant difference in survival, though major adverse events occurred more frequently with the use of resin microspheres.

Graphical Abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in hepatocellular carcinoma: from the right to the left of BCLC. Cardiovasc Intervent Radiol. 2022;45(11):1599–607.CrossRefPubMed
2.
Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients With hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.CrossRefPubMed
3.
Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.CrossRefPubMed
4.
Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29.CrossRefPubMed
5.
Salem R, Johnson GE, Riaz A, Bishay VL, Kim E, Padia S. Yttrium-90 glass microspheres in the treatment of hepatocellular carcinoma: the LEGACY study. Cardiovasc Intervent Radiol. 2020;43(Suppl 4):163.
6.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.CrossRefPubMed
7.
Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.CrossRefPubMed
8.
Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt 2):S223-229.CrossRefPubMed
9.
Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25(7):455–61.CrossRefPubMed
10.
Lam M, Garin E, Maccauro M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340–52.CrossRefPubMedPubMedCentral
11.
Watanabe M, Grafe H, Theysohn J, et al. Voxel-based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with (90)Y glass microspheres. J Nucl Med. 2023;64(7):1102–8.CrossRefPubMed
12.
Van Der Gucht A, Jreige M, Denys A, et al. Resin versus glass microspheres for (90)Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry. J Nucl Med. 2017;58(8):1334–40.CrossRefPubMed
13.
Kallini JR, Gabr A, Thorlund K, et al. Comparison of the adverse event profile of TheraSphere((R)) with SIR-Spheres((R)) for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol. 2017;40(7):1033–43.CrossRefPubMed
14.
Biederman DM, Titano JJ, Tabori NE, et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol. 2016;27(6):812–21.CrossRefPubMed
15.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRefPubMed
16.
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–50.CrossRefPubMed
17.
Korean Liver Cancer A, National Cancer Center K. KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2022;23(12):1126–240.CrossRef
18.
Kwon JH, Kim GM, Han K, et al. Safety and efficacy of transarterial radioembolization combined with chemoembolization for bilobar hepatocellular carcinoma: a single-center retrospective study. Cardiovasc Intervent Radiol. 2018;41(3):459–65.CrossRefPubMed
19.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.CrossRefPubMed
20.
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–6.CrossRefPubMed
21.
Frantz S, Matsuoka L, Vaheesan K, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN registry. J Vasc Interv Radiol. 2021;32(6):845–52.CrossRefPubMed
22.
Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.CrossRefPubMed
23.
Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.CrossRefPubMed
24.
Cardarelli-Leite L, Chung J, Klass D, et al. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43(3):411–22.CrossRefPubMed
25.
Golfieri R, Bilbao JI, Carpanese L, et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59(4):753–61.CrossRefPubMed
26.
Pasciak AS, Abiola G, Liddell RP, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47(4):816–27.CrossRefPubMed
27.
Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342–52.CrossRefPubMed
Metadaten
Titel
Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere
verfasst von
Gyoung Min Kim
Do Young Kim
Jong Yun Won
Sungmo Moon
Seung Up Kim
Beom Kyung Kim
Publikationsdatum
14.05.2024
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 9/2024
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-024-03726-9

Weitere Artikel der Ausgabe 9/2024

Interventional Radiology: A True Medical Specialty

  • LETTER TO THE EDITOR

Trans-umbilical Venous Approach for Embolization of Congenital Hepatic Haemangioma via Patent Ductus Arteriosus in a Preterm Neonate

  • Letter To The Editor

Detection of Endoleak after Endovascular Aortic Repair through Deep Learning Based on Non-contrast CT

  • Clinical Investigation

Glass or Resin: The Ends Justify the Means?

  • Commentary

Endovascular Treatment of Unruptured Pancreatic Arcade Aneurysms

  • Clinical Investigation

“Andreas Grüntzig Would like to Read this Article”

  • Commentary

Neu im Fachgebiet Radiologie

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Röntgen-Thorax oder LDCT fürs Lungenscreening nach HNSCC?

Personen, die an einem Plattenepithelkarzinom im Kopf-Hals-Bereich erkrankt sind, haben ein erhöhtes Risiko für Metastasen oder zweite Primärmalignome der Lunge. Eine Studie hat untersucht, wie die radiologische Überwachung aussehen sollte.

Statine: Was der G-BA-Beschluss für Praxen bedeutet

Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise